Select language:  
1800 620 420
Close menu

Flynn’s one in 1.2 million diagnosis

To mark Rare Disease Day, Laura Winter shares the remarkable story of how her four-year-old son, Flynn has survived an extremely rare blood cancer diagnosis.

  • Other blood cancers
Read more
Flynn Winter

I needed better information about clinical trial options

Matthew Fogarty has spent almost five years regularly travelling to the other side of the world to collect the handful of pills that keep his blood cancer at bay.

  • Other blood cancers
Read more
Matthew Fogarty

Support Australians to survive blood cancer with simple stem cell donation

  • Media releases
  • Other blood cancers
Read more

You stepped up for Jack and his family in their darkest hour

Jack was 22 years old when he was diagnosed with a dangerous blood disorder called aplastic anaemia.

  • Other blood cancers
  • Treatments and side-effects
Read more

“Thank you for bringing us together”

Our supporters help people going through blood cancer to make connections.

  • Other blood cancers
Read more

Making sure someone’s always there

Rhys was put in contact with Leukaemia Foundation Blood Cancer Support Coordinator, Amber to help him navigate through his blood cancer journey.

  • Other blood cancers
Read more
Rhys Marshall during treatment

Daniela is back on her feet after blood cancer

She was just 24 and had recently immigrated to Australia from Slovakia before she was diagnosed with a rare and aggressive form of blood cancer called lymphoma.

  • Other blood cancers
Read more
Daniela

Conquering aplastic anaemia and lymphoma

Luci was a healthy 28-year-old when she wasdiagnosed with a blood disorder leading to a second blood cancer diagnosis.

  • Blood disorders
  • Other blood cancers
Read more

Third trimester blood cancer diagnosis rocks young family

At 36 weeks pregnant, Jocelyn was diagnosed with APML.

  • Other blood cancers
Read more
Jocelyn Raunjak with her three daughters, Rebecca, Samantha and Michelle in the hospital

Decisions from the March PBAC meeting for CLL/SLL

Acalabrutinib (Calquence®) will be added to the therapy arsenal for CLL and SLL.

  • Advocacy and policy
  • Chronic lymphocytic leukaemia
  • Other blood cancers
  • Treatments and side-effects
Read more